<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04138394</url>
  </required_header>
  <id_info>
    <org_study_id>VICToRY</org_study_id>
    <nct_id>NCT04138394</nct_id>
  </id_info>
  <brief_title>VItamin C in Thermal injuRY: The VICToRY Pilot Trial</brief_title>
  <acronym>VICToRY</acronym>
  <official_title>VItamin C in Thermal injuRY: The VICToRY Pilot Trial A Feasibility Study for a Seamless Adaptive Phase II/II Multi-center Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Evaluation Research Unit at Kingston General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinical Evaluation Research Unit at Kingston General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to show that giving high dose, intravenous vitamin C in addition to standard&#xD;
      care to burned critically ill patients will be associated with less organ dysfunction,&#xD;
      improved survival and a quicker rate of recovery. In this study, all patients will receive&#xD;
      standard care and of the patients will also receive high dose intravenous vitamin C, while&#xD;
      the other half of patients will receive placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In certain disease states, such as those associated with severe burns and other critical&#xD;
      illnesses, the relationship between nutrient deficiencies, altered immune status, and&#xD;
      acquired infection has been recognized for many years. More than in any other injury, the&#xD;
      inflammation and catabolism associated with severe burns can exacerbate nutrient&#xD;
      deficiencies, thereby predisposing patients to impaired immune function and increased risk of&#xD;
      developing infectious complications, organ dysfunction, and death. We aim to conduct a&#xD;
      large-scale, multi-center randomized trial to evaluate the effect of high-dose (200mg/kg/day&#xD;
      x 96 hours) intravenous vitamin C in addition to standard of care (SOC) on 28-days composite&#xD;
      outcome of Persistent Organ Dysfunction (POD) and all-cause mortality compared to add-on&#xD;
      placebo and SOC. Patients will be allocated to 2 groups, active or control: patients in the&#xD;
      active group will receive intravenous vitamin C at 200mg/kg in divided doses, every 6 hrs for&#xD;
      96 hrs. Patients in the control group will receive a similar amount of placebo (either D5W or&#xD;
      saline) delivered in the same manner as the vitamin C. This study will be the first large&#xD;
      international multi-centre trial examining the effects of high dose intravenous vitamin C in&#xD;
      burn patients. It represents a unique collaboration of burn units worldwide that is&#xD;
      coordinated by the Clinical Evaluation Research Unit, based in Kingston Ontario Canada, a&#xD;
      coordinating center that has demonstrated the ability to run multi-center trials and&#xD;
      translate findings into practice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 24, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients will be allocated to receive intravenous vitamin C at 200mg/kg in divided doses, every 6 hrs for 96 hrs. We justify this proposed dosing strategy as the proposed dose of vitamin C has been shown to be safe and effective in patients with sepsis and lung injury whereas prior dosing strategies used in the burns literature (66 mg/kg/24 hours) have safety issues and are not long enough in duration. Control group: patients will receive a similar amount of placebo (either D5W or saline) delivered in the same manner as the vitamin C.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Allocation will be random and concealed and will be blinded to everyone except the pharmacist at each site. The vitamin C will be sourced locally and prepared in a blinded manner by local research pharmacies that will be responsible for preparing study samples and delivering them to the ICU in a blinded fashion. The randomization system, which has proven reliable in several prior RCTs, has a robust audit trail, and will maintain concealment and blinding.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of conducting the protocol</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluation of feasibility metrics to determine compliance with the study protocol, lost to follow-up and consent failure rates, and enrollment rates to assess the feasibility of conducting the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxidation-reduction potential (ORP)</measure>
    <time_frame>96 hours</time_frame>
    <description>Oxidation-reduction potential (ORP), or redox-status measured at 96 hrs (end of treatment period).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PODS+death</measure>
    <time_frame>90 days</time_frame>
    <description>Persistent organ dysfunction (PODS)+death, a novel composite endpoint that combines being alive and being free of organ support (inotropes or vasopressors, renal replacement therapy and mechanical ventilation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Discharge Alive</measure>
    <time_frame>90 days</time_frame>
    <description>Time to discharge alive from hospital, a composite of mortality and length of stay is similar to &quot;ventilator- free days&quot;, which is a widely accepted and commonly used outcome in intensive care research.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>90 days</time_frame>
    <description>Duration of time in the ICU</description>
  </other_outcome>
  <other_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>90 days</time_frame>
    <description>Length of time on mechanical ventilation, including still on mechanical ventilation at time of discharge.</description>
  </other_outcome>
  <other_outcome>
    <measure>ICU readmission rate</measure>
    <time_frame>90 days</time_frame>
    <description>Incidents of readmission to ICU from within the hospital</description>
  </other_outcome>
  <other_outcome>
    <measure>Hospital mortality</measure>
    <time_frame>90 days</time_frame>
    <description>Did the patient die in hospital or was the patient discharged?</description>
  </other_outcome>
  <other_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>90 days</time_frame>
    <description>Duration of time in the hospital</description>
  </other_outcome>
  <other_outcome>
    <measure>Wound healing</measure>
    <time_frame>90 days</time_frame>
    <description>time-to-95% graft closure</description>
  </other_outcome>
  <other_outcome>
    <measure>Gram negative bacteremia</measure>
    <time_frame>90 days</time_frame>
    <description>Venous or arterial blood cultures that show bacteremia with Gram-negative bacilli</description>
  </other_outcome>
  <other_outcome>
    <measure>6 month mortality</measure>
    <time_frame>6 months</time_frame>
    <description>Is the patient alive or deceased 6 months post admission.</description>
  </other_outcome>
  <other_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>Administration of the SF-36 questionnaire 6 months post admission</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Shock</condition>
  <condition>Thermal Burn</condition>
  <arm_group>
    <arm_group_label>Vitamin C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive intravenous vitamin C at 200mg/kg in divided doses, every 6 hrs for 96 hrs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive a similar amount of placebo (either D5W or saline) delivered in the same manner as the vitamin C.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ascorbic Acid</intervention_name>
    <description>We will conduct a double-blind, randomized controlled pilot trial of 90 patients with severe burns randomly allocated to receive intravenous vitamin C (200 mg/kg/day for 96 hours) or placebo (45 per group). If feasibility is demonstrated in the pilot, a larger phase III component will be conducted and aimed at lowering morbidity and mortality and reducing health care costs in an otherwise very devastating and disabling injury worldwide.</description>
    <arm_group_label>Vitamin C</arm_group_label>
    <other_name>vitamin C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Patients will receive a similar amount of placebo (either D5W or saline) delivered in the same manner as the vitamin C.</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>saline</other_name>
    <other_name>D5W</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Deep 2nd and/or 3rd degree burns requiring skin grafting&#xD;
&#xD;
          -  Minimum burn size of =&gt;25% Total Body Surface Area (TBSA)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &gt;24 hours from admission to ICU or burn unit to assessment.&#xD;
&#xD;
          -  Patients admitted to burn unit &gt;24 from injury or accident.&#xD;
&#xD;
          -  Patients who are moribund (not expected to survive the next 72 hours).&#xD;
&#xD;
          -  Pregnancy (pregnancy will be ruled out as part of standard of care) or lactating.&#xD;
&#xD;
          -  Enrollment in another industry sponsored ICU intervention study (co-enrollment in the&#xD;
             RE-ENERGIZE trial is allowed).&#xD;
&#xD;
          -  Receiving high-dose IV vitamin C already (enteral or oral vitamin C is allowed).&#xD;
&#xD;
          -  Known glucose-6-phosphate dehydrogenase (G6PD) deficiency.&#xD;
&#xD;
          -  Recent history of kidney stones (within the last year).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daren K Heyland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen's University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maureen Dansereau</last_name>
    <phone>613-549-6666</phone>
    <phone_ext>6686</phone_ext>
    <email>maureen.dansereau@queensu.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Burn Center Valleywise Health</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Richey</last_name>
      <phone>602-344-5751</phone>
      <email>Karen.Richey2@valleywisehealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Claudia Islas</last_name>
      <phone>602-344-1246</phone>
      <email>Claudia.Islas@valleywisehealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Kevin Foster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital-USF</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Smith, MD</last_name>
      <email>dsmith3@health.usf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Joseph M Still RF, Doctors Hospital</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruce Bruce Friedman</last_name>
      <email>brucefriedman.md@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals &amp; Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucy Wibbenmeyer, MD</last_name>
      <email>Lucy-wibbenmeyer@uiowa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Claire Johnson, RC</last_name>
      <email>claire-johnson@uiowa.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Lucy Wibbenmeyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jonathan Pollack, MD</last_name>
      <email>Jonathan.Pollack@mercy.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Medical Center</name>
      <address>
        <city>Ohio City</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jon Jon Wisler, MD</last_name>
      <email>Jon.Wisler@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southwestern Medical Center - University of Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kareem Abdelfattah, MD</last_name>
      <email>Kareem.abdelfattah@UTSouthwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kathryn Naumann, RC</last_name>
      <email>Kathryn.Naumann@UTSouthwestern.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Harborview Medical Center - Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sam Mandell, MD</last_name>
      <email>mandells@uw.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ghent University Hospital</name>
      <address>
        <city>Ghent</city>
        <state>Oost Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kirsten Collpaert, MD</last_name>
      <email>Kirsten.colpaert@ugent.be</email>
    </contact>
    <contact_backup>
      <last_name>Jolien Van Hecke, RC</last_name>
      <phone>32 9 332 21 42</phone>
      <email>Jolien.VanHecke@UZGENT.be</email>
    </contact_backup>
    <investigator>
      <last_name>Kirsten Colpaert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Belgium Military Hospital, Military Hospital</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Rose, MD</last_name>
      <email>thomas.rose@vub.ac.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Liege</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne-Françoise Rousseau, MD</last_name>
      <email>afrousseau@chu.ulg.ac.be</email>
    </contact>
    <contact_backup>
      <last_name>Marjorie Fadeur, RC</last_name>
      <email>marjorie.fadeur@chu.ulg.ac.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre, Ross Tilley Burn Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah Rehou</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>7998</phone_ext>
      <email>Sarah.Rehou@sunnybrook.ca</email>
    </contact>
    <contact_backup>
      <last_name>Sydney Rotman</last_name>
      <phone>416-480-6100</phone>
      <email>sydney.rotman@sunnybrook.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Marc Jeschke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de recherche du CHUM</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali Ghamraoui</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>20093</phone_ext>
      <email>ali.ghamraoui.chum@ssss.gouv.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Maya Salame</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>35289</phone_ext>
      <email>maya.salame.chum@ssss.gouv.qc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Sylvain Belisle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Québec-Université Laval, Hôpital de lènfant Jésus</name>
      <address>
        <city>Québec</city>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Bellemare</last_name>
      <phone>418-525-4444</phone>
      <phone_ext>66060</phone_ext>
      <email>David.Bellemare@crchudequebec.ulaval.ca</email>
    </contact>
    <contact_backup>
      <last_name>Eve Cloutier</last_name>
      <phone>418-525-4444</phone>
      <phone_ext>66487</phone_ext>
      <email>eve.cloutier@crchudequebec.ulaval.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Alexis Turgeon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>RWTH Aachen University, Aachen</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Justus Beir, MD</last_name>
      <email>jbeier@ukaachen.de</email>
    </contact>
    <contact_backup>
      <last_name>Aileen Hill, MD</last_name>
      <email>ahill@ukaachen.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Manheim Medical Center, Hospitals of Cologne</name>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ulrich Limper, MD</last_name>
      <email>Ulrich.limper@dlr.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Berufsgenossenschaftliche Unfallklinik Ludwigshafen</name>
      <address>
        <city>Ludwigshafen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gabriel Hundeshagen, MD</last_name>
      <email>gabrielhundeshagen@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Würzburg</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick Meybohm, MD</last_name>
      <email>meybohm_p@ukw.de</email>
    </contact>
    <contact_backup>
      <last_name>Christian Stoppe, MD</last_name>
      <email>christian.stoppe@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Central Dr. Ignacio Morones Prieto</name>
      <address>
        <city>San Luis Potosí</city>
        <zip>78290</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Martinez, MD</last_name>
      <email>dr.mamj@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Nacional del Quemado y Cirugías Reconstructivas</name>
      <address>
        <city>Asunción</city>
        <country>Paraguay</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daisy Grau, MD</last_name>
      <email>daigrau@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chelsea and Westminster Hospital</name>
      <address>
        <city>Chelsea</city>
        <state>London</state>
        <zip>SW10 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Declan Collins, MD</last_name>
      <email>Declan.Collins@chelwest.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Mindelsohn Way</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Naiem Moiemen, MD</last_name>
      <email>naiem.moiemen2@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Helens and Knowsley Hospitals NHS Trust</name>
      <address>
        <city>Prescot</city>
        <zip>L35 5DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kayvan Shokrollahi, MD</last_name>
      <email>Kayvan.Shokrollahi@sthk.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Mid Yorkshire Hospitals NHS Trust</name>
      <address>
        <city>Wakefield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Preetha Muthayya, MD</last_name>
      <email>Preetha.Muthayya@midyorks.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Mexico</country>
    <country>Paraguay</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 21, 2019</study_first_submitted>
  <study_first_submitted_qc>October 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2019</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clinical Evaluation Research Unit at Kingston General Hospital</investigator_affiliation>
    <investigator_full_name>Daren K. Heyland</investigator_full_name>
    <investigator_title>Dr. Daren Heyland, MD, MSc, FRCPC</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

